Thrombin inhibitors

A compound of the general formula

• 110
• or a pharmaceutically acceptable salt thereof, wherein
• m is 0, 4, or 2;
• Rw and Rv are independently selected from the group consisting of hydrogen, C1-4 alkyl, and halogen;
• Rt is C1-6 alkyl or C3-7 cycloalkyl;
• R1 is selected from the group consisting of 1)
• 111
• wherein
• R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-4 alkoxy, C1-6 alkyl, —OH, and cyano, and
• X is a bond, O, or S, and
• 112
• wherein
• R6 is selected from the group consisting
• a) hydrogen,
• b) C1-6alkyl,
• c) —OH,
• d) —NR24R25, where R24 and R25 are independently hydrogen, or C1-6 alkyl unsubstituted or substituted with one or more of —OH, —COOH, C3-7 cycloalkyl, or COOR17, where R17 is C1-6alkyl,
• e) NHC(O)OR18,
• f) NHC(O)R15,
• g) NHC(O)NHR18,
• h) NHSO2R16,
• i) NHC(O)NH2, and
• j) NHCN,
• wherein R18 is selected from the group consisting of C1-6 alkyl, aryl, and C3-7 cycloalkyl;
• R7 and R8 are independently selected from the group consisting of
• a) hydrogen,
• b) —CF3,
• c) C1-6 alkyl,
• d) phenyl, unsubstituted or substituted with C1-6 alkyl, COOR26 or halogen, where R26 is C1-6 alkyl or hydrogen,
• 113
• f) C3-7 cycloalkyl,
• 114
• where R27 is C1-6 alkyl or C3-7 cycloalkyl,
• 115
• wherein Rx and Ry are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, unsubstituted phenyl or phenyl substituted with halogen, C1-4 alkyl, OH, or C1-4 alkoxy, and
• wherein n is 0, 1, 2 or 3,
• i) C1-6 alkyl substituted with one or two of the group consisting of
• i) C3-7 cycloalkyl, either unsubstituted or substituted with C1-4 alkyl,
• ii) —COOH,
• iii) —OH,
• 116
• wherein R9 and R10 are independently selected from the group consisting of
• aa) hydrogen,
• bb) halogen,
• cc) C1-4 alkoxy,
• dd) C1-4 alkyl,
• ee) hydroxy,
• ff) CF3,
• gg) cyano,
• hh) COOR28, where R28 is C1-4 alkyl or hydrogen;
• or R7 and R8 are joined to form a C3-7 carbocyclic ring which is unsubstituted or independently substituted with one or two C1-6 alkyl groups;
• R3 is selected from the group consisting of
• 1) —C(R11)(R12)C(R13)(R14)N(R15)(R16),
• 2) —C(R13)(R14)N(R15)(R16), and
• 117
• where n is 0, 1 or 2,
• wherein
• R11 and R12 are independently selected from the group consisting of
• a) hydrogen,
• b) F,
• c) C1-4 alkyl,
• d) CF3,
• e) CHF2,
• f) C3-7 cycloalkyl,
• or R11 and R12 together form a 3-7 membered carbocyclic ring,
• R13 and R14 are independently selected from the group consisting of
• a) hydrogen,
• b) C1-4 alkyl
• c) —CF3,
• d) —CHF2,
• e) —CH2OH,
• f) C3-6 cycloalkyl,
• or R13 and R14 together form a 3-7 membered carbocyclic ring,
• R15 and R16 are independently selected from the group consisting of
• a) hydrogen,
• b) C1-6 alkyl, unsubstituted or substituted with —OH, C3-7 cycloalkyl, or C(O)OR19, wherein R19 is selected from the group consisting of hydrogen and C1-6 alkyl,
• c) C3-7 cycloalkyl, and
• d) —C(O)R20, wherein R20 is selected from the group consisting of —OR and —NHR21, and wherein R21 is hydrogen, C1-6 alkyl or benzyl,
• or R15 and R16 are joined to form a 4-7 membered heterocyclic ring which is unsubstituted or substituted with hydroxyl or halogen.